We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
Read MoreHide Full Article
According to an Israeli newspaper, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is expected to reduce its workforce by about 4000. Consequently, shares of the company were up by more than 5% in the pre-market trading on Nov 20. However, so far this year, the stock has been down 62.8% compared with the industry’s decline of 30.2%.
As per the daily, Teva is also planning to lay off its current president of global research and development and its chief scientific officer, Michael Hayden.
Meanwhile, the company is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load.
The U.S. generics industry is also confronting significant competitive and pricing pressure, thereby affecting the company’s top-line performance. Also, an increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. The challenges in the U.S. generics market are expected to continue this year and probably in the next as well.
The company’s lead branded drug, Copaxone, is witnessing declining sales for quite some time now. In October 2017, Mylan launched (at-risk) its generic version of the 40 mg formulation much earlier than expected, which was a in a major blow to Teva.
Since 2015, Glatopa — a generic version of Copaxone 20 mg — is already being marketed by Momenta and Novartis’ (NVS - Free Report) generic arm, Sandoz, while Mylan launched its version of the 20 mg formulation in October.
Additionally, the company’s profitability is hurt by a huge debt burden accrued as a result of Teva’s $40.5 billion acquisition of Allergan’s generic unit, Allergan Generics, in 2016.
In order to combat these challenges, Teva has divested some non-core assets to cut its significant debt load. The rumors of the workforce reduction plan probably cheered investors as it will save costs of the company. It remains to see if these efforts are enough to revive the company’s fortune in this challenging scenario, especially as it faces erosion of its largest product, Copaxone.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Teva (TEVA) Stock Rises 5% on Reports of Massive Job Cuts
According to an Israeli newspaper, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) is expected to reduce its workforce by about 4000. Consequently, shares of the company were up by more than 5% in the pre-market trading on Nov 20. However, so far this year, the stock has been down 62.8% compared with the industry’s decline of 30.2%.
As per the daily, Teva is also planning to lay off its current president of global research and development and its chief scientific officer, Michael Hayden.
Meanwhile, the company is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load.
The U.S. generics industry is also confronting significant competitive and pricing pressure, thereby affecting the company’s top-line performance. Also, an increase in FDA generic drug approvals and ongoing customer consolidation are resulting in additional competitive pressure in the industry. The challenges in the U.S. generics market are expected to continue this year and probably in the next as well.
The company’s lead branded drug, Copaxone, is witnessing declining sales for quite some time now. In October 2017, Mylan launched (at-risk) its generic version of the 40 mg formulation much earlier than expected, which was a in a major blow to Teva.
Since 2015, Glatopa — a generic version of Copaxone 20 mg — is already being marketed by Momenta and Novartis’ (NVS - Free Report) generic arm, Sandoz, while Mylan launched its version of the 20 mg formulation in October.
Additionally, the company’s profitability is hurt by a huge debt burden accrued as a result of Teva’s $40.5 billion acquisition of Allergan’s generic unit, Allergan Generics, in 2016.
In order to combat these challenges, Teva has divested some non-core assets to cut its significant debt load. The rumors of the workforce reduction plan probably cheered investors as it will save costs of the company. It remains to see if these efforts are enough to revive the company’s fortune in this challenging scenario, especially as it faces erosion of its largest product, Copaxone.
Zacks Rank
Teva has a Zacks Rank #5 (Strong Sell).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>